KR20050086948A - 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법 - Google Patents

인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법 Download PDF

Info

Publication number
KR20050086948A
KR20050086948A KR1020057012139A KR20057012139A KR20050086948A KR 20050086948 A KR20050086948 A KR 20050086948A KR 1020057012139 A KR1020057012139 A KR 1020057012139A KR 20057012139 A KR20057012139 A KR 20057012139A KR 20050086948 A KR20050086948 A KR 20050086948A
Authority
KR
South Korea
Prior art keywords
insulin
glucagon
administration
administered
hypoglycemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057012139A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 트레버 그린
로버트 알. 헨리
Original Assignee
디오벡스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디오벡스, 인코포레이티드 filed Critical 디오벡스, 인코포레이티드
Publication of KR20050086948A publication Critical patent/KR20050086948A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
KR1020057012139A 2002-12-27 2003-12-23 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법 Ceased KR20050086948A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43673502P 2002-12-27 2002-12-27
US60/436,735 2002-12-27
US45497203P 2003-03-14 2003-03-14
US60/454,972 2003-03-14
US47034603P 2003-05-13 2003-05-13
US60/470,346 2003-05-13

Publications (1)

Publication Number Publication Date
KR20050086948A true KR20050086948A (ko) 2005-08-30

Family

ID=32719167

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057012139A Ceased KR20050086948A (ko) 2002-12-27 2003-12-23 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법

Country Status (11)

Country Link
US (2) US7314859B2 (https=)
EP (1) EP1578437A4 (https=)
JP (1) JP2006514990A (https=)
KR (1) KR20050086948A (https=)
CN (1) CN1732012A (https=)
AU (1) AU2003303634B2 (https=)
CA (1) CA2509755A1 (https=)
MX (1) MXPA05006994A (https=)
NO (1) NO20053537L (https=)
NZ (1) NZ541365A (https=)
WO (1) WO2004060387A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020130751A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DK1808438T3 (da) 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2005056087A1 (en) * 2003-12-05 2005-06-23 Cardinal Health 303, Inc. Patient-controlled analgesia with patient monitoring system
KR20070029276A (ko) * 2004-06-29 2007-03-13 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
WO2007011958A2 (en) * 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
CA2913805A1 (en) * 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
IN2015DN00888A (https=) 2006-02-22 2015-07-10 Mannkind Corp
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
WO2009055742A2 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Delivery of active agents
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US10624577B2 (en) 2008-04-04 2020-04-21 Hygieia, Inc. Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
CA2720304C (en) 2008-04-04 2018-05-15 Hygieia, Inc. Apparatus for optimizing a patient's insulin dosage regimen
US9220456B2 (en) 2008-04-04 2015-12-29 Hygieia, Inc. Systems, methods and devices for achieving glycemic balance
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
US8992464B2 (en) 2008-11-11 2015-03-31 Hygieia, Inc. Apparatus and system for diabetes management
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9375529B2 (en) * 2009-09-02 2016-06-28 Becton, Dickinson And Company Extended use medical device
US8573027B2 (en) 2009-02-27 2013-11-05 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
EP2335755A1 (en) 2009-12-17 2011-06-22 Sanofi-Aventis Deutschland GmbH Device and method for delivery of two or more drug agents
EP2552951A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
EP3062841B1 (en) * 2013-10-24 2023-06-28 Trustees of Boston University Infusion system employing an infusion set for preventing mischanneling of multiple medicaments
WO2015100439A1 (en) 2013-12-26 2015-07-02 Tandem Diabetes Care, Inc. Integration of infusion pump with remote electronic device
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
MX2016010599A (es) 2014-02-18 2016-11-18 Novo Nordisk As Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
JP7001584B2 (ja) * 2015-09-04 2022-01-19 ラティチュード ファーマシューティカルズ インコーポレイテッド 安定化されたグルカゴン溶液
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
WO2018144867A1 (en) * 2017-02-03 2018-08-09 Vanderbilt University Systems, compositions and methods for treating diabetes
KR102495891B1 (ko) * 2020-03-04 2023-02-06 이오플로우(주) 약액 제어 주입 디바이스
WO2022010698A1 (en) * 2020-07-07 2022-01-13 The Regents Of The University Of California Therapeutic hybrid microneedle patch for the delivery of insulin and glucagon
CA3215858A1 (en) 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound
GB202109087D0 (en) 2021-06-24 2021-08-11 Norwegian Univ Sci & Tech Ntnu Therapeutic methods and devices

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB748857A (en) 1952-12-16 1956-05-09 Nyegaard & Co As Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity
GB766994A (en) 1953-11-13 1957-01-30 Novo Terapeutisk Labortorium A Improved process in crystallization of insulin
GB766995A (en) 1953-11-14 1957-01-30 Novo Terapeutisk Labor As Improvements in or relating to the production of insulin crystals
US2902408A (en) * 1957-09-12 1959-09-01 Organon Suspensions of drugs destined for injection and process for the preparation thereof
GB831907A (en) 1957-09-12 1960-04-06 Organon Labor Ltd Suspensions of drugs destined for injection and process for the preparation thereof
GB844434A (en) 1958-01-31 1960-08-10 Organon Nv Insulin preparations and process for preparing same
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US4003379A (en) * 1974-04-23 1977-01-18 Ellinwood Jr Everett H Apparatus and method for implanted self-powered medication dispensing
US4498843A (en) * 1982-08-02 1985-02-12 Schneider Philip H Insulin infusion pump
IT1170375B (it) * 1983-04-19 1987-06-03 Giuseppe Bombardieri Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
US4538616A (en) * 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
AT391998B (de) * 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US4879273A (en) 1987-05-22 1989-11-07 The Rockefeller University Glucagon homologs and therapeutic use thereof
NL8701644A (nl) 1987-07-13 1989-02-01 Cordis Europ Inrichting voor dosering in het lichaam van een vloeibaar materiaal.
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US5190041A (en) * 1989-08-11 1993-03-02 Palti Yoram Prof System for monitoring and controlling blood glucose
US5101814A (en) * 1989-08-11 1992-04-07 Palti Yoram Prof System for monitoring and controlling blood glucose
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5527771A (en) * 1991-01-10 1996-06-18 Amylin Pharmaceuticals, Inc. Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
SG49239A1 (en) * 1991-05-24 1998-05-18 Amylin Pharmaceuticals Inc Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US5512468A (en) * 1993-11-12 1996-04-30 Stratagene Process of producing highly transformable bacterial cells and cells produced thereby
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
NL9401886A (nl) 1994-05-27 1996-01-02 Dsm Nv Samenstelling bestaande uit een dendrimeer en een in het dendrimeer opgesloten actieve stof, een werkwijze voor de bereiding van een dergelijke samenstelling en een werkwijze voor het vrijgeven van de actieve stof.
US5474552A (en) * 1994-06-27 1995-12-12 Cb-Carmel Biotechnology Ltd. Implantable drug delivery pump
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
EP0816381B1 (en) 1995-03-10 2004-01-14 NAKAMURA, Toshikazu Polyethylene glycol modified hepatocyte growth factor (hgf)
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5741211A (en) * 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
IL124831A0 (en) 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
EP0914094A4 (en) * 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
ATE342729T1 (de) 1997-01-15 2006-11-15 Phoenix Pharmacologics Inc Modifizierter tumor-nekrosefaktor
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US5869062A (en) * 1997-05-27 1999-02-09 Oliver; Benjamin Skin treatment composition
US5919216A (en) * 1997-06-16 1999-07-06 Medtronic, Inc. System and method for enhancement of glucose production by stimulation of pancreatic beta cells
US6093167A (en) * 1997-06-16 2000-07-25 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
US6437092B1 (en) * 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
RU2205188C2 (ru) * 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
JP2002531518A (ja) * 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
US20020114829A1 (en) * 1998-12-18 2002-08-22 Hayat Onyuksel Materials and methods for making improved liposome compositions
US6360888B1 (en) * 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
US6261280B1 (en) * 1999-03-22 2001-07-17 Medtronic, Inc Method of obtaining a measure of blood glucose
AU763039B2 (en) * 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
US6319510B1 (en) * 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
BR0010750A (pt) * 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6461331B1 (en) * 1999-05-21 2002-10-08 Minimed Inc. Device and method for infusion of small molecule insulin mimetic materials
US20020026141A1 (en) * 1999-11-04 2002-02-28 Medtronic, Inc. System for pancreatic stimulation and glucose measurement
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
WO2001064149A1 (en) * 2000-02-29 2001-09-07 Jie Zhang Improved transdermal drug patch
US6572542B1 (en) * 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
WO2002022154A2 (en) 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
WO2002032957A1 (en) 2000-10-16 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
AU2002230509A1 (en) 2000-11-28 2002-06-11 Martin G. Baum Devices and methods for treating low blood sugar levels
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US6656590B2 (en) * 2001-01-10 2003-12-02 Cabot Corporation Coated barium titanate-based particles and process
US6824521B2 (en) * 2001-01-22 2004-11-30 Integrated Sensing Systems, Inc. Sensing catheter system and method of fabrication
EP1565437A1 (en) * 2002-11-18 2005-08-24 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1881786B1 (en) 2005-05-13 2017-11-15 Trustees of Boston University Fully automated control system for type 1 diabetes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020130751A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 인슐린 및 글루카곤을 포함하는 약학 조성물

Also Published As

Publication number Publication date
CA2509755A1 (en) 2004-07-22
CN1732012A (zh) 2006-02-08
EP1578437A4 (en) 2006-08-09
US7642232B2 (en) 2010-01-05
MXPA05006994A (es) 2005-10-18
EP1578437A1 (en) 2005-09-28
AU2003303634B2 (en) 2009-10-01
JP2006514990A (ja) 2006-05-18
NO20053537L (no) 2005-08-26
US20080096801A1 (en) 2008-04-24
AU2003303634A1 (en) 2004-07-29
NZ541365A (en) 2009-09-25
US20060160722A1 (en) 2006-07-20
WO2004060387A1 (en) 2004-07-22
US7314859B2 (en) 2008-01-01

Similar Documents

Publication Publication Date Title
US7314859B2 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
JP2006514990A5 (https=)
TWI614024B (zh) 超快起作用胰島素之用途
US10137172B2 (en) Administration regime
WO2013177565A1 (en) Insulin-pramlintide compositions and methods for making and using them
CN102202683A (zh) 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
US8003605B2 (en) Minimising body weight gain in insulin treatment
CN105188736A (zh) 胰岛素给药方案
KR20070029276A (ko) 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
Daugherty Review of insulin therapy
Umpierrez et al. Concentrated insulins: clinical update of therapeutic options
Profit ExuberaŴ (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes
Thomas et al. Inhaled insulin: A much-needed needleless paradigm shift in diabetes management
ZA200504944B (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
HK1108567A (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
Hermansen Insulin and new insulin analogues, insulin pumps and inhaled insulin in type 1 diabetes
HK1085123A (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
Patel et al. Dr. Shweta Bhanot Pandit
Tuncel et al. Insulin Analogs Applied with Continuous Subcutaneous Insulin Infusion (Pump) in the Treatment of Diabetes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20081215

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101130

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20101130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I